Unfortunately, no specific drug therapy is currently available on the market for the reduction of Lp(a) levels, standard drugs for the treatment of dyslipidaemia do not show sufficient effect on Lp(a) levels, and the risk of re-events may not be adequately reduced by LDL-C reduction alone [3]. The gene discussed is LPA; the disease is inherited lipid metabolism disorder.